508
Participants
Start Date
December 31, 2010
Primary Completion Date
August 31, 2012
Study Completion Date
September 30, 2012
BAY86-5300
0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser supported by a reminder function
BAY86-5300
0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser without reminder support
Córdoba
Milan
Hamburg
Brescia
Pavia
Boadilla del Monte
Málaga
Toulouse
Blankenburg
Magdeburg
Burg
Bologna
Modena
Wuppertal
Olivet
Siena
Nancy
Pisa
Frankfurt am Main
Biarritz
Heidelberg
Paris
Paris
Marly-le-Roi
Napoli
Palermo
Catania
Paris
Paris
Strasbourg
Gera
Kahla
Cagliari
Roma
Elda
Barcelona
Chesterfield
Nottingham
Bath
East Horsley
Bradford-on-Avon
Corsham
Cardiff
Lead Sponsor
Bayer
INDUSTRY